Adenosine-based cell therapy approaches for pharmacoresistant epilepsies

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Pharmacoresistant epilepsy remains a significant challenge despite advances in treatment.
• Adenosine, an endogenous neuromodulator, exhibits antiepileptic and neuroprotective effects.
• Systemic administration of adenosine is limited by significant peripheral and central side effects.

Purpose of the Study:

• To explore the potential of local adenosine augmentation for treating pharmacoresistant epilepsy.
• To establish the rationale for adenosine-based cell therapies.
• To review recent approaches for adenosine-based cell therapies.

Main Methods:

• Investigated deficits in the adenosinergic system associated with epileptogenesis.
• Utilized focal paracrine delivery of adenosine from encapsulated cells in a rat epilepsy model.
• Assessed anticonvulsant activity in epilepsy models resistant to conventional antiepileptic drugs.

Main Results:

• Deficits in the adenosinergic system correlate with and promote seizures.
• Local delivery of adenosine from encapsulated cells effectively suppressed seizures in kindled rats.
• Adenosine's anticonvulsant effects were observed even in drug-resistant epilepsy models, without apparent side effects.

Conclusions:

• Restoring an inhibitory adenosinergic tone is a viable therapeutic strategy for epilepsy.
• Focal, cell-based delivery of adenosine offers a promising approach to mitigate side effects.
• Adenosine-based cell therapies represent a novel and potentially effective treatment for pharmacoresistant epilepsies.